Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Counterfeit Medicine is a growing global threat. At Pfizer, a dedicated team is leading the fight to stop these dangerous ...

W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...

Progressive stays No. 1 in radio ad rankings for August 4–10, as Pfizer leaps into the top 5 and Lenovo returns for ...

Kennedy, who has long expressed skepticism about the safety and efficacy of certain vaccines, said the move signals a broader ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

New York hospitals that get discounted drugs through a controversial federal program are gearing up for a new pilot that they ...

Here are two beaten-down stocks that long-term investors might want to consider buying on the dip and holding for several ...